Cemiplimab-rwlc

ImmunotherapyApproved for: NSCLC NSCLC patients tumors with high PD-L1 expression and without EGFR, ALK, ROS1 aberrations. Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal TIM-3 lung cancer trial after phase 2...
|
February 25, 2021
|